Amgen Inc (AMGN)

AMGN (NASDAQ:Drugs)
$133.02
pos +0.00
+0.00%
Today's Range: 0.00 - 0.00 | AMGN Avg Daily Volume: 2,912,800
Last Update: 08/19/14 - 3:59 PM EDT
Volume: 0
YTD Performance: 16.60%
Open: $0.00
Previous Close: $133.02
52 Week Range: $103.88 - $133.98
Oustanding Shares: 759,607,230
Market Cap: 101,194,875,181
6-Month Chart
TheStreet Ratings Grade for AMGN
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 5 6 8 8
Moderate Buy 2 1 1 1
Hold 8 10 10 10
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 2.17 2.21 2.08 2.08
Latest Dividend: 0.61
Latest Dividend Yield: 1.83%
Dividend Ex-Date: 08/12/14
Price Earnings Ratio: 20.40
Price Earnings Comparisons:
AMGN Sector Avg. S&P 500
20.40 20.40 28.56
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
18.68% 27.33% 155.91%
GROWTH 12 Mo 3 Yr CAGR
Revenue 8.20 0.24 0.07
Net Income 16.90 0.10 0.03
EPS 20.30 0.40 0.12
Earnings for AMGN:
EBITDA 7.35B
Revenue 18.68B
Average Earnings Estimates
Qtr (09/14) Qtr (12/14) FY (12/14) FY (12/15)
Average Estimate $2.09 $2.16 $8.10 $8.78
Number of Analysts 3 3 3 3
High Estimate $2.15 $2.24 $8.18 $9.04
Low Estimate $2.02 $2.09 $7.99 $8.56
Prior Year $1.93 $1.81 $7.57 $8.10
Growth Rate (Year over Year) 8.29% 19.15% 6.96% 8.48%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
Amgen's gain is pure insanity from a stock picker's point of view.
These quality names look appealing on the basis of 30-week moving average.
Bullish
Jul 30, 2014 | 7:13 AM EDT
Shares of AMGN now seen reaching $135, according to Credit Suisse. Estimates also increased, given the company's new guidance. Neutral ...
On a daily time frame, as long as it holds a key support level, it's a possible buy.
Hologic, Symantec and TE Connectivity could all benefit from the current M&A binge.
For now, just let the market do the heavy lifting for you.

Biotechs Flash the Green Light Real Money Pro($)

After a decline, the sector has built a base, and these names are breaking out.
Spice up your portfolio with some takeover bait.
Its pipeline appears strong enough to overcome patent-expiration issues.
If the stock doesn't breach support, here's where I'd buy in.

Columnist Conversations

With now several sessions of aggressive selling in the Yen and Euro futures contracts, a few (negative) moment...
Market looks it will pause on the open after two solid days of gains to open week. Interesting piece in MW by ...
Bulls ran up the score with even more on another half percent gain to extend the recovery rally. The reversal...
Lang:
Yesterday presented us with a great opportunity to take some profits into a nice market rally. This is what w...

REAL MONEY'S BEST IDEAS

Columnist Tweets

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.